Dendritic cell (DC)-based vaccines have been applied clinically in the setting of advanced-stage cancer. To date, the clinical efficacy of these vaccines has been limited, possibly owing to the impairment of transferred DC function in cancer-bearing patients. In this study, we examined the therapeutic efficacy of interleukin-12 (IL-12) gene-transfected DCs isolated from tumor-bearing hosts against liver tumor. The endogenous DCs isolated from subcutaneous (s.c.) CMS4 tumor-bearing mice (CMS4DC) exhibited decreased expression levels of antigen-presenting molecules and low-allostimulatory capacity. CMS4DC produced less IL-12p70 than DCs isolated from normal mice. Adenoviral transfection of IL-12 gene into CMS4DC (AdIL12DC) restored the expression of antigen-presenting molecules and allostimulatory capacity. Intratumoral (i.t.) delivery of AdIL12DC resulted in complete rejection of intrahepatic CMS4 tumors and activation of innate and acquired immune cells. Antibody depletion studies revealed that both CD4 + and CD8
Introduction
Dendritic cells (DCs) effectively elicit immune responses to self and foreign antigens. 1 As these specialized antigen-presenting cells (APCs) can induce the generation of both antigen-specific cytotoxic T lymphocytes (CTL) and T-helper cells, DC-based vaccines are attractive strategies for the treatment of cancer. In this regard, DCs pulsed with tumor-associated antigens in various forms, including whole-cell lysates, 2 peptides, 3 proteins, 4 RNA, 5 or DNA, 6 have proven effective in eliciting protective and therapeutic tumor antigen-specific immunity in murine models. The results of several DC-based tumor vaccine trials have also recently been reported for late-stage cancer patients with B-cell lymphoma, melanoma, prostate cancer and renal cell carcinoma. [7] [8] [9] [10] Although tumor-specific T cells were promoted by vaccination in most patients, objective clinical responses have thus far only been observed in a minority of treated individuals. In several cancers, the functional activity of DCs isolated from advanced cancer patients has been reported to be significantly impaired, and this might be associated with the limited clinical efficacy of DC-based cancer vaccines applied to these individuals. 11, 12 Hence, these modest current clinical successes observed for DC-based cancer vaccines might be expected to improve if study designs were modified in order to optimize DC promotion of Th1-type immunity in cancer-bearing hosts.
Interleukin-12 (IL-12) exhibits a number of immunologically important activities, including the ability to enhance NK cell and CTL functionality, 13, 14 to polarize CD4 + T-cell responses by preferentially supporting the Th1/Tc1-type, and to suppress Th2-type immunity. 15 Previous reports demonstrated potent antitumor effects associated with IL-12 gene therapy using IL-12 gene-modified tumor cells 16 and DCs 17 in murine tumor models. In cancer patients, DCs are often found in an immature and hypostimulatory state. 18 Grohmann et al. 19 demonstrated that IL-12 directly activates DC by signals mediated by IL-12 receptors expressed on DCs. Thus, IL-12 transfection into DCs isolated from cancer patients might be expected to lead to recovery of their impaired function via a positive feedback loop.
The liver contains a large compartment of innate immune cells (NK cells, NKT cells, as well as DCs). DCs contribute to innate immune responses by activating NK cells in both cell-to-cell contact-dependent and -independent manners. [20] [21] [22] Thus, DCs secreting abundant IL-12 would be expected to activate both T cells and NK cells in the liver that could prove therapeutic. Primary and metastatic liver tumors are the most common malignancies that resist conventional chemotherapy and radiotherapy, and present with a poor prognosis. In this setting, the development of novel and more effective immunotherapy has been necessitated especially for advanced liver cancer. Toward this end, we present two novel findings in the present report: (1) IL-12 transfection of DCs restores the impaired phenotype/function of endogenous DCs isolated from tumor-bearing animals and (2) intratumoral (i.t.) injection of IL-12 genetransduced DCs activates both innate and acquired immunity that is, therapeutic in the setting of a liver tumor model.
Results
Phenotype, allostimulatory capacity and cytokine production of endogenous DCs isolated from tumorbearing mice
We initially validated the phenotype and allostimulatory capacity of, and IL-12p70 production by DCs isolated from subcutaneous (s.c.) CMS4 tumor-bearing mice (CMS4DC). Flow cytometric examination revealed that CMS4DC displayed significantly decreased levels of expression of the major histocompatibility complex (MHC) class II antigens and the CD80 costimulatory molecules when compared to DCs isolated from normal mice (N-DC) (Po0.05, Figure 1a ). The expression of CD86 molecule on CMS4DC tended to decrease although it was not significant (P ¼ 0.07). The decreased expressions of these molecules on DCs were also observed in Colon26 mouse colon cancer tumor-bearing mice (data not shown). Mixed leukocyte reaction (MLR) experiments revealed that CMS4DC exhibited significantly lower allogeneic T-cell proliferation than N-DC (Po0.05, Figure 1b ). To evaluate IL-12 production from DCs, CMS4 DC and N-DC were treated with or without LPS. Two days later, the supernatants of the DC cultures were harvested and analyzed using mouse IL-12p70-specific enzyme-linked immuno-sorbent assay (ELISA). Notably, IL-12p70 production from LPS-treated CMS4DC was significantly lower than that from LPS-treated N-DC (Po0.05, Figure 2a ).
Phenotypical and functional normalization of CMS4DC after ex vivo infection with AdIL12
CMS4DC were infected with recombinant adenoviruses and then analyzed 48 h later for their phenotype and IL-12p70 production capacity ( Figure 2b ). As expected, CMS4DC infected with adenoviruses encoding mouse IL-12 (AdIL12DC) secreted significantly higher levels of IL-12p70 than CMS4DC infected with adenoviral mock vector (Adc5DC) or noninfected N-DC (Po0.05). AdIL12DC also displayed significantly elevated levels of the MHC class II antigens when compared to Adc5DC, approximating the levels observed for N-DC (Po0.05, Figure 1a ). The expressions of CD80 and CD86 costimulatory molecules on AdIL12DC also tended to increase to the levels of N-DC. MLR experiments revealed that AdIL12DC possessed significantly more stimulatory capacity than CMS4DC for the proliferation of allogeneic T cells (Po0.05, Figure 1b) . These results suggest that AdIL12 gene transfer into CMS4DC restores their impaired antigen presenting function of CMS4DC. Immunotherapy using IL-12 gene-transduced DCs T Tatsumi et al 3a and b, although the liver weight of the Adc5DC treatment group was significantly lighter than that of the phosphate-buffered saline (PBS) treatment group (Po0.05), large CMS4 liver tumors were formed in both PBS-treated and Adc5DC-treated mice. The liver weight of the AdIL12DC treatment group was significantly lighter than that of Adc5DC or PBS treatment group (Po0.05), and no CMS4 tumor formation was observed in livers of AdIL12DC-treated mice, suggesting the strong therapeutic efficacy of i.t.-delivered AdIL12DC.
We evaluated the degree of systemic (i.e. serum) interferon gamma (IFN-g) produced in the treated animal as a result of IL-12-based gene therapy, that might reflect the Th1-type immune responses in treated animals. As shown in Figure 3c , the serum IFN-g level detected in AdIL12DC-treated mice was significantly higher than that observed in either Adc5DC-or PBS-treated mice (Po0.05). 
P<0.05
Figure 2 IL-12 production from DCs generated from CMS4 tumorbearing mice (a) and from adenovirus-infected DCs generated from CMS4 tumor-bearing mice (b). (a) Bone marrow-derived DCs were generated from mice bearing established s.c. 28 day CMS4 tumor (CMS4DC) or normal mice (N-DC). On day 7, DCs were stimulated with (CMS4DC+LPS, N-DC+LPS) or without LPS (CMS4DC, N-DC). On day 9, the supernatants of DC cultures were harvested and subjected to mouse IL-12p70 ELISA. (b) CMS4DC were adenovirally infected with AdIL12 (AdIL12DC) or Adc5 (Adc5DC). At 48 h after adenoviral transfection, the supernatant of DCs cultures were harvested and subjected to mouse IL-12p70 ELISA. Cytokine levels are reported in pg/ml (mean7s.d. of triplicate samples). Similar results were obtained in two independent experiments. N.D., not detected. Immunotherapy using IL-12 gene-transduced DCs T Tatsumi et al city than those from PBS-treated mice against both YAC-1 cells and CMS4 cells. MNCs from AdIL12DC-treated mice showed the highest level of cytotoxicity when compared with those from Adc5DC-or PBS-treated mice (Po0.05).
We also examined whether the treatment of AdIL12DC against CMS4 liver tumor generated anti-CMS4 CTL. Splenocytes were obtained from treated mice 14 days after i.t. injection of AdIL12DC, and were cocultured with mitomycin C (MMC)-treated CMS4 cells for 5 days. As shown in Figure 4c , splenocytes from AdIL12DC-treated mice displayed significantly stronger cytolytic activity against CMS4 cells than those from either Adc5DC-or PBS-treated mice (Po0.05). The cytolytic activity of splenocytes from AdIL12DC-treated mice was completely reduced by CD8 + T-cell depletion, but not by CD4 + T-cell depletion, demonstrating that CD8 + T cells were the main effector cells of the cytolytic activity of splenocytes from AdIL12DC-treated mice (data not shown).
These results suggested that i.t. injection of AdIL12DC in the liver could activate hepatic NK cells and generate anti-CMS4 CTL most efficiently.
Depletion of CD4 + , CD8 + T cells or NK cells abolished the antitumor efficacy of AdIL12DC-based treatment
To examine that the therapeutic benefit of the AdIL12DC-based regimen in CMS4 liver tumor model was T cell and/or NK cell dependent, we performed T-cell subset depletion and NK-cell depletion studies. Depletion of either CD4 + or CD8 + T cells significantly inhibited the antitumor effects associated with i.t. injections of AdIL12DC (Po0.05, Figure 5a ). NK cell depletions also significantly inhibited the antitumor efficacy of this therapy (Po0.05, Figure 5b ). These results suggested that both CD8 + and CD4 + T cells as well as NK cells each play critical roles in the benefits associated with AdIL12DC-based therapy.
AdIL12DC was superior to the combination of CMS4DC and AdIL12 injection in the liver tumor treatment
To examine whether i.t. injection of AdIL12DC was superior to the i.t. combined injection of CMS4DC and AdIL12 vector against CMS4 sarcoma liver tumor, we performed additional control experiments. Mice bearing CMS4 liver tumor were treated with AdIL12DC or the combination of CMS4DC and AdIL12. The amount of each Ad injected and the numbers of DCs were equivalent in both treatment groups. As shown in Figure  5c , although the liver weight of the combination of CMS4DC and AdIL12 treatment group was significantly lighter than that of the PBS treatment group (Po0.05), the liver weight of the AdIL12DC treatment group was significantly lighter than that of the combination of CMS4DC and AdIL12 treatment group (Po0.05). These results suggest that i.t. delivered AdIL12DC was superior to the combination of i.t. delivered CMS4DC and AdIL12 in the therapeutic efficacy.
Prolonged, systemic CMS4 tumor-specific immunity resulted from i.t. injection of AdIL12DC
We next tried to determine whether the treatment of a CMS4 sarcoma lesion in the liver would impact the progression of a consequent s. 6 AdIL12DC or the combination of 1 Â 10 6 CMS4DC and the same amount of AdIL12 vector as we generated AdIL12DC (each treatment group N ¼ 6). Two weeks after the tumor injection, the livers of treated mice were removed. *Po0.05.
Immunotherapy using IL-12 gene-transduced DCs T Tatsumi et al presentation and that these APC produced less IL-12p70 than DCs isolated from healthy donor mice, which may lead to inferior type-1 immunity in the tumor microenvironment. Although the functional impairment of DCs might be correlated with the tumor-derived immunosuppressive factors, such as TGFb, IL-10 and vascular endothelial growth factor, 18 details of the dominant mechanisms underlying impaired DC function are still a topic of active investigation. Most of the current clinical trials using DCs were conducted for patients with advanced cancer. Several human studies showed that the deficient antigen-presenting capacity of the DCs found in patients with advanced cancer induces a cellularimmune deficit. 11, 12 These studies suggested that DCs from advanced cancer patients might not have sufficient capacity for inducing tumor antigen-specific immune responses. This is consistent with our tumor experiments that DCs from tumor-bearing mice did not elicit sufficient antitumor effect in CMS4 liver tumor. Clearly, there is a great need to enhance the impaired capacity of DCs from advanced-stage cancer patients in order to provide an optimized DC-based vaccine.
Currently, although many reports of DC-based vaccine in mouse tumor models have been published, few have evaluated the antitumor effect of DCs prepared from tumor-bearing mice. Our present data demonstrated that AdIL12DC generated from cancer-bearing animals exhibit normalized functionality; that is, restored expressions of molecules associated with antigen-presenting capacity and restore MLR function. It has been reported that activation of IL-12 receptor on DCs by IL-12 promotes nuclear localization of NF-kB, which regulates the expression of these (MHC and costimulatory) molecules and that IL-12 also regulates DC immunostimulatory function. 19 Thus, IL-12 production as a consequence of AdIL12 infection may serve as a positive feedback stimulus correcting tumor-induced dysfunction in DCs.
Although both Adc5 infection and AdIL12 infection enhanced MHC class I expression on CMS4 sarcoma cells and Colon26, colon cancer cells, only AdIL12, but not Adc5, enhanced MHC class I expression on DCs (Tatsumi T, unpublished data). These data were consistent with Nielsch's report that high levels of MHC class I expression in adenovirus-infected tumor cells were due to a combinatorial stimulation of two cis-regulatory sequences of the MHC class I promoters: NF-kB binding site and the interferon stimulated response element. 23 In the current study, for tumor experiments, both AdIL12DC and Adc5DC were washed twice before use. After these procedures, both AdIL12DC and Adc5DC were injected intrahepatically with tumor cells. Thus, in our tumor model, the influence of adenovirus transfection on tumor cells seems to be weak.
Our results also demonstrated that CMS4 sarcoma tumors in the liver can be treated effectively by i.t. injection with AdIL12DC. Significant systemic toxicities have been previously reported for combined recombinant IL-12+recombinant IL-18 protein-based therapy in murine tumor models, 24 with similar complications anticipated in human clinical trials. 25 Furumoto et al. 26 demonstrated that DCs offer the best cytokine delivery system because the DC delivery system minimizes systemic toxicity of cytokines, such as IL-12, and is simultaneously capable of promoting the most efficient immune responses affecting the tumor microenvironment. Clearly, local production of IL-12 in the tumor microenvironment would be expected to induce effective antitumor immunity and prevent systemic toxicity. In this study, although i.t. co injection of DCs and AdIL12 resulted in significant inhibition of CMS4 liver tumor, i.t. injection of AdIL12DC is significantly superior to that of combination of DCs and AdIL12 in the antitumor effect in the liver. Taken together, we believe that i.t. delivery of AdIL12DC may optimally promote antitumor effects in the mouse liver tumor microenvironment. We have shown that serum IFN-g concentrations in AdIL12DC-treated mice were significantly elevated vs those in control mice. Zitvogel et al. 27 reported that the antitumor effects of DC-based vaccination were dependent on the production of Th1-associated cytokines such as IFN-g, tumor necrosis factor alpha and IL-12. Therefore, enhanced IFN-g production resulting from i.t. injection of AdIL12DC may also play an important role in the increased antitumor activity in vivo.
A normal liver contains lymphocytes that are usually enriched with NK cells and NKT cells; that is, 25% NK cells and 30% NKT cells in contrast to peripheral blood that contains only 10% NK cells and 5% NKT cells. 28, 29 Recently, DCs have been implicated in the activation of NK cells in both mice and human. 20, 21, 30 During NK cell activation by DCs, both soluble factors and cell-to-cell contact seem to be important. Of the soluble factors involved in this process, IL-12 exhibits a number of important biological activities, including the ability to enhance NK cell and CTL activities. Based on these results, intrahepatic injection of AdIL12DC would be anticipated to induce strong activation of both NK cells and CTL. Our present report shows that both CD8 + and CD4 + T cells, as well as, NK cells play critical roles in the therapeutic benefits associated with a comparable therapy of intrahepatic tumors. We also found that early activation of liver NK cells by i.t. injection of AdIL12DC were observed in the cytolytic activity against both YAC-1 (NK sensitive) cells and CMS4 cells, and that CMS4 tumor-specific CTL were generated after rejection of CMS4 liver tumor by AdIL12DC treatment. These findings support the ability of AdIL12DC to activate the liver-associated NK cells, which may partially contribute to eradication of tumor cells and to generate CMS4 tumor-specific CTL. Additional experiments using a subcutaneous (s.c.) rechallenge with tumor suggested that i.t. AdIL12DC treatment of liver sarcoma tumors not only blocks treated liver tumor progression, but protects against consequent 'recurrence' of that same tumor at a distal site via the induction of systemic immunity mediated by CD4 + and CD8 + T cells. In spite of recent progress and early successes reported for DC-based cancer immunotherapies, there is significant room for improvement in these regimens, especially in the setting of advanced primary and metastatic liver cancer. Thus, new therapeutic approaches of DC-based immunotherapy to advanced liver tumor need to be developed. Recently percutaneous liver tumor ablation methods, radiofrequency ablation therapy and ethanol injection therapy, were well established in hepatocellular carcinoma treatment, and these methods encourage us to apply i.t. injection-immunotherapy to liver tumor treatment. We have shown here that adenoviral transfection of IL-12 cDNA into DCs could 
Materials and methods

Mice
Six-to-eight-week-old female BALB/c mice were purchased from Shizuoka Experimental Animal Laboratory (Shizuoka, Japan), and maintained in micro-isolator cages. Animals were handled under aseptic conditions. Procedures were performed according to approved protocol and in accordance with recommendations for the proper care and use of laboratory animals.
Cell lines and culture
CMS4 is a chemically induced BALB/c sarcoma and has been described previously. 17 Colon26, a mouse colon adenocarcinoma cell line, was kindly provided by Dr Takashi Tsuruo (Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan). These cell lines were maintained in complete medium (CM, Roswell Park Memorial Institute-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 10 mM L-glutamine: all reagents from GIBCO/Life Technologies, Grand Island, NY, USA) in a humidified incubator at 5% CO 2 tension and 371C. . Bone marrow-derived DCs from CMS4 tumor-bearing mice (CMS4DC) and normal mice (N-DC) were generated as previously described with minor modifications. 17 Briefly, BALB/c bone marrow cells were cultured in CM supplemented with 1000 U/ml of granulocyte-macrophage colony-stimulating factor and mIL-4 (PeproTech EC, London, UK) for 7 days. CD11c + DCs were then isolated from whole bone marrow culture by magnetic cell sorting using MACS (Miltenyi Biotec, Gladbach, Germany) according to the manufacturer's protocol.
Flow cytometry
For phenotypic analysis of DCs, PE-or fluorescein isothiocyanate-conjugated monoclonal antibodies against mouse cell surface molecules (CD11c, CD40, CD80 and CD86 (all from BD-Pharmingen, San Diego, CA, USA), MHC class II antigens (Miltenyi Biotec)), and appropriate isotype controls were used and flow cytometric analysis was performed using a FACScan (Becton Dickinson, San Jose, CA, USA) flow cytometer. The results of flow cytometric analysis are reported in arbitrary mean fluorescence intensity (MFI) units.
MLR
MLR were performed to evaluate allostimulatory function of DCs as previously described with minor modification. 31 DCs were seeded in triplicate (10-2.5 Â 10 3 cells/well) for use as stimulator cells. Allogeneic (C57/BL6) splenic responder T cells (2 Â 10 4 ) were added to DCs (at indicated T cell: DC ratios) and cultured for 48 h. To evaluate the proliferation of allogeneic T cells, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium, salt) assay (Nacalai Tesque, Kyoto, Japan) was performed according to the manufacturer's protocol. The 450 nm absorbance was measured using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA), with the results expressed as the mean optical density (O.D.)7s.d. of three independent experiments.
Mouse IL-12 production from adenovirally transduced CMS4DCs
Five million (day 7 cultured) CMS4DCs were infected with recombinant adenoviruses encoding mouse IL-12 (AdIL12DC; MOI ¼ 50) and mock vector (Adc5DC; MOI ¼ 50), as previously reported. 17 After 48 h, adenovirus-infected CMS4DCs were harvested and analyzed for phenotype and function. Culture supernatants were also collected for measurement of mouse IL-12 production using a species-specific IL-12p70 ELISA kit (BDPharmingen), with a lower level detection limit of 62.5 pg/ml. For tumor experiments, both AdIL12DC and Adc5DC were washed twice with PBS before use. 
IFN-g ELISA
Mice serum was harvested 2 weeks after intrahepatic tumor injection and AdIL12DC treatment, and subjected to mouse IFN-g ELISA (BD-Pharmingen), with lower detection limit of 31.3 pg/ml.
Cytotoxic assay
BALB/c mice were treated with an i.t. injection of 1 Â 10 6 AdIL12DC against CMS4 liver tumor. After 48 h, hepatic MNCs were prepared as described previously. 32 To evaluate the activation of hepatic NK cells, WST-8 was performed as described previously with minor modifications. 17 After 24 h coculture of hepatic MNC and NKsusceptible YAC-1 target cells or CMS4 cells at a 1:1 ratio in 96-well plates, 10 ml WST-8 was added into each well Immunotherapy using IL-12 gene-transduced DCs T Tatsumi et al and the cells were incubated for another 1 h. The 450 nm absorbance was measured using a microplate reader as described above. NK cell cytotoxicity was calculated as described previously. 17 To evaluate the generation of CTL against CMS4 cells by treatment of AdIL12DC, 51 Cr release assay was performed. Splenocytes were harvested from treated mice 14 days after i.t. injection of AdIL12DC against CMS4 liver tumor, and were cocultured with MMC-treated CMS4 cells for 5 days as described previously. 31 Lymphocytes were harvested after 5 days in vitro stimulation and subjected to 4 h 51 Cr release assay against CMS4 target.
31 Assays were performed in triplicate, with spontaneous release of all assays never exceeding 25% of the maximum release.
T-cell and NK-cell depletion experiments
On days À6, À1, 5 and 10 after tumor inoculation, mice were injected intraperitoneally with anti-CD4 (GK1.5 hybridoma, American-Type Culture Collection, ATCC, Rockville, MD, USA) or anti-CD8 (53-6.72 hybridoma, ATCC) as previously described. 17 For NK-cell depletion, mice were injected with anti-asialo GM-1 (WAKO, Osaka, Japan) on days À1, 5 and 10 after tumor inoculation. The efficiency of specific subset depletions was validated by flow cytometry analysis of splenocytes using PE-conjugated anti-CD4 and anti-CD8 mAbs or PE-conjugated anti-DX5 mAbs (all Pharmingen). In all cases, 99% of the targeted cell subset was specifically depleted (data not shown).
Statistical analysis
Statistical significance of differences between the groups was determined by applying a Student's t-test or twosample t-test with Welch correction after each group had been tested with equal variance and Fisher's exact probability test. The statistical significance of the differences in more than two groups was determined by applying one-way analysis of variance. Statistical significance was defined as Po0.05.
